Broker-Dealer Regulation

On March 1, 2023, the U.S. Department of Justice (DOJ) unsealed an indictment against the CEO of a publicly traded healthcare company (the Executive) relating to charges of an insider trading scheme. The indictment represents the first time the DOJ has brought criminal insider trading charges stemming from an executive’s use of a Rule 10b5-1 trading plan. The investigation is part of a data-driven initiative led by the DOJ’s Fraud Section to identify executive abuses of 10b5-1 trading plans.Continue Reading DOJ Brings First Criminal Charges Stemming From Use of Rule 10b5-1 Trading Plan